Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Publications

Soper, JT, Secord, AA, Havrilesky, LJ, Berchuck, A, and Clarke-Pearson, DL. "Rectus abdominis myocutaneous and myoperitoneal flaps for neovaginal reconstruction after radical pelvic surgery: comparison of flap-related morbidity." Gynecol Oncol 97, no. 2 (May 2005): 596-601.

Full Text

Soper, JT, Havrilesky, LJ, Secord, AA, Berchuck, A, and Clarke-Pearson, DL. "Rectus abdominis myocutaneous flaps for neovaginal reconstruction after radical pelvic surgery." Int J Gynecol Cancer 15, no. 3 (May 2005): 542-548.

Full Text

Secord, AA. "Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer - Reply." GYNECOLOGIC ONCOLOGY 96, no. 1 (January 2005): 265-266.

Full Text

Ferrero, S, Ragni, N, and Secord, AA. "Vascular endothelial growth factor, persistent disease, and survival in ovarian cancer [2] (multiple letters)." Gynecologic Oncology 96, no. 1 (2005): 265-266.

Full Text

Berchuck, A, Secord, AA, Havrilesky, LJ, Wenham, R, Soper, JT, and Clarke-Pearson, DL. "Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer." July 15, 2004.

Scholars@Duke

Secord, AA, Jones, E, Hahn, CA, Havrilesky, LJ, Soper, JT, Berchuck, A, Clarke-Pearson, DL, and Prosnitz, LR. "Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer." July 15, 2004.

Scholars@Duke

Berchuck, A, Secord, AA, Havrilesky, LJ, Wenham, R, Soper, JT, and Clarke-Pearson, DL. "Phase I/II trial of combination topotecan and vinorelbine in patients with refractory gynecologic cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 5152-.

Scholars@Duke

Secord, AA, Jones, E, Hahn, CA, Havrilesky, LJ, Soper, JT, Berchuck, A, Clarke-Pearson, DL, Prosnitz, LR, and Dewhirst, MW. "Phase I/II trial of intravenous liposomal doxorubicin and whole abdomen hyperthermia in patients with refractory ovarian cancer." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, no. 14_suppl (July 2004): 5089-.

Scholars@Duke

Alvarez Secord, A, Sayer, R, Snyder, SA, Broadwater, G, Rodriguez, GC, Berchuck, A, and Blackwell, K. "The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer." Gynecol Oncol 94, no. 1 (July 2004): 74-79.

Full Text

Moller, KA, Gehrig, PA, Van Le, L, Secord, AA, and Schorge, J. "The role of optimal debulking in advanced stage serous carcinoma of the uterus." Gynecol Oncol 94, no. 1 (July 2004): 170-174.

Full Text

Pages